Reaction
Ectropion reporting signals
As of the last recalculation, Ectropion appears in 330 FAERS reports alongside 9 co-occurring drug terms. The strongest observed disproportionality signal is PANITUMUMAB (PRR 81.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Panitumumab | 19 | 81.1 | 81.2 |
| Brentuximab Vedotin | 10 | 63.4 | 63.5 |
| Timolol Maleate | 9 | 58.9 | 58.9 |
| Erlotinib | 4 | 26.4 | 26.4 |
| Erlotinib Hydrochloride | 5 | 25.6 | 25.6 |
| Brimonidine Tartrate | 7 | 25.3 | 25.3 |
| Irinotecan Hydrochloride | 5 | 24.9 | 24.9 |
| Vismodegib | 3 | 21.4 | 21.4 |
| Lifitegrast | 3 | 11.7 | 11.7 |